- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03480945
Glycemic Control and Endothelial Function in Patients With Type 2 Diabetes (AIDdiabetes)
Evaluation of the Mechanism Underlying Endothelial Dysfunction in Patients With Type 2 Diabetes With Poor and Optimized Glycaemic Control
Study objective To evaluate the mechanism behind endothelial dysfunction in patients with type 2 diabetes in relation to the level of glycaemic control.
Primary endpoint: Change in endothelium dependent vasodilatation (EDV).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is performed on one group of patients with type 2 diabetes and one group of age-matched healthy controls
Inclusion criteria:
- Type 2 diabetes
- Poor glycaemic control defined as a mean day blood glucose >12 mmol/L.
Exclusion criteria:
- Age >80 years.
- HbA1c <70 mmol/mol
- Myocardial infarction/unstable angina within 6 weeks prior to the study.
- Treatment with oral anticoagulants (Warfarin or New oral anticoagulants)
- Raynaud's phenomenon, peripheral vasculopathies, arterial shunting or other vascular surgery of the study arm.
- Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol.
- Participant in an ongoing study.
- Unwillingness to participate following oral and written information.
Healthy controls Inclusion criteria
1. No medical history of cardiovascular disease 2. Fasting blood glucose <6.0 mmol/l or plasma glucose <7.0 mmol/l Exclusion criteria
- Age >80 years.
- Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol.
- Participant in an ongoing study.
- Unwillingness to participate following oral and written information.
Endothelium-dependent vasodilatation is determined by venous occlusion plethysmography during intra-arterial infusion of serotonin (21, 70 and 210 ng/min). Endothelium-independent vasodilatation is determined by infusion of sodium nitroprusside (SNP; 1, 3 and 10 µg/min). Each dose is given for 2 min at a rate of 2.5 ml/min.
Sixteen patients and age-matched healthy controls are included. On the day of the study the subject arrives to the laboratory after having a light breakfast. Forearm vessels of the non-dominant arm are cannulated and forearm blood flow is determined as described above. Baseline endothelium dependent and endothelium independent vasodilatation is determined by intra-arterial infusions of serotonin and SNP, respectively, during an intra-arterial infusion of saline. Thereafter an intra-arterial infusion of the arginase inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA) is started and is maintained for 120 min at a rate of 0.1 mg/min. The dose is based on a previous study by our group demonstrating improved endothelial function. Endothelium-dependent and -independent vasodilatation is reassessed at 120 min of infusion.
Following determination of baseline endothelial function (poor glycemic control), the patients are put on optimized glucose lowering therapy with insulin and/or oral glucose lowering medication according to clinical routine at the day-care center of the department of Endocrinology, Karolinska University Hospital for at least 8 weeks. Treatment target is mean day blood glucose <9 mmol/L and fasting blood glucose 4-6 mmol/L. After this, endothelium-dependent and -independent vasodilatation before and following arginase inhibition is re-assessed as described above.The healthy control group is only investigated on one occasion.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 17176
- Karolinska Institutet, Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Study Population
Description
Inclusion Criteria:
- Type 2 diabetes
- Poor glycaemic control defined as a mean day blood glucose >12 mmol/L.
Exclusion Criteria:
- Age >80 years.
- HbA1c <70 mmol/mol
- Myocardial infarction/unstable angina within 6 weeks prior to the study.
- Treatment with oral anticoagulants (Warfarin or New oral anticoagulants)
- Raynaud's phenomenon, peripheral vasculopathies, arterial shunting or other vascular surgery of the study arm.
- Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol.
- Participant in an ongoing study.
- Unwillingness to participate following oral and written information.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endothelial function
Time Frame: 8 weeks
|
Change in endothelium-dependent dilatation
|
8 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Serotonin Agents
- Serotonin Receptor Agonists
- Nitric Oxide Donors
- Serotonin
- Nitroprusside
Other Study ID Numbers
- AIDdiabetes
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on serotonin
-
Zeynep Kamil Maternity and Pediatric Research and...CompletedPostpartum DepressionTurkey
-
University of ChicagoNational Institute on Drug Abuse (NIDA)Completed
-
Ohio State UniversityWithdrawnDementia | Alzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Eli Lilly and CompanyCompletedMajor Depressive Disorder (MDD)United States, Puerto Rico, Finland, Japan, Slovakia, Czechia, Croatia
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited States, Germany, Italy, Turkey, Russian Federation, Korea, Republic of, Greece, France, Croatia, Romania, Spain, Argentina, Puerto Rico, Belgium, Mexico, Slovakia
-
Cairo UniversityNot yet recruitingDepression | FibromyalgiaEgypt
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited Kingdom, United States, Belgium, Austria, Australia, Germany, Sweden
-
Guang'anmen Hospital of China Academy of Chinese...Ministry of Science and Technology of the People´s Republic of ChinaCompleted
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited States, South Africa, Poland, Ukraine, Japan, Russian Federation, Latvia